Novanta Inc. (NOVT)
| Market Cap | 5.51B +20.0% |
| Revenue (ttm) | 1.03B +7.6% |
| Net Income | 61.76M +0.7% |
| EPS | 1.58 -6.4% |
| Shares Out | 37.82M |
| PE Ratio | 92.14 |
| Forward PE | 36.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 421,170 |
| Open | 145.83 |
| Previous Close | 151.18 |
| Day's Range | 143.60 - 149.83 |
| 52-Week Range | 98.27 - 176.38 |
| Beta | 1.72 |
| Analysts | Strong Buy |
| Price Target | 194.50 (+33.44%) |
| Earnings Date | Nov 9, 2026 |
About NOVT
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment s... [Read more]
Financial Performance
In 2025, Novanta's revenue was $980.60 million, an increase of 3.30% compared to the previous year's $949.25 million. Earnings were $53.83 million, a decrease of -16.01%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NOVT stock is "Strong Buy." The 12-month stock price target is $194.5, which is an increase of 33.44% from the latest price.
News
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2026 resul...
How to Build a Humanoid Body
Last month we broke down the three key areas needed to build your own humanoid. We have already looked at the companies behind the technologies required to build a humanoid's brain.
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta price target raised to $194 from $180 at Baird
Baird raised the firm’s price target on Novanta (NOVT) to $194 from $180 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and…
Novanta Earnings Call Transcript: Q2 2026
Delivered 9% organic and 10% reported sales growth in Q2 2026, with all business units growing organically and strong margin expansion. Closed the Riverpoint Medical acquisition, raising full-year guidance to over 15% reported revenue growth and accelerating manufacturing transformation. Bookings, new product launches, and cash flow reached record levels.
Novanta Earnings release: Q2 2026
Novanta released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Novanta Quarterly report: Q2 2026
Novanta has published its Q2 2026 quarterly earnings report on August 6, 2026.
Novanta reports Q2 EPS 89c, consensus 83c
Reports Q2 revenue $265.8M, consensus $262.3M. “Novanta (NOVT) delivered an exceptional second quarter, exceeding expectations across revenue, margins, and profitability,” said Matthijs Glastra, Chair...
Novanta sees Q3 adjusted EPS 95c-$1.00, consensus 94c
Sees Q3 revenue $300M-$304M, consensus $262.82M. Sees Q3 adjusted EBITDA $74M-$77M.
Novanta sees FY26 adjusted EPS $3.68-$3.74, consensus $3.59
Sees FY26 revenue $1.13B-$1.14B, consensus $1.05B. Sees adjusted EBITDA $273M-$278M.
Novanta Announces Financial Results for the Second Quarter 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta completes acquisition of Riverpoint Medical
Novanta (NOVT) announced that it has completed the acquisition of Riverpoint Medical from Arlington Capital Partners. The transaction is expected to generate a high single-digit return on invested cap...
Novanta Completes Acquisition of Riverpoint Medical
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has ...
Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 resu...
Novanta registers to sell 2.14M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.14M common shares. The company is not selling any shares under…
Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta Transcript: M&A announcement
The acquisition of Riverpoint Medical accelerates expansion into high-growth surgical consumables, is immediately accretive, and brings significant synergies and recurring revenue growth. The deal strengthens market position, leverages existing customer relationships, and sets a platform for future expansion.
Novanta Slides: M&A announcement
Novanta has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Novanta Press release: M&A announcement
Novanta issued a press release on June 9, 2026, disclosing material business information to investors.
Novanta price target raised to $180 from $173 at Baird
Baird analyst Quinn Fredrickson raised the firm’s price target on Novanta (NOVT) to $180 from $173 and keeps an Outperform rating on the shares.
Novanta announces $300M private placement
Novanta (NOVT) announced that it has entered into a securities purchase agreement for a private placement of the company’s common shares to institutional and other accredited investors that is expecte...
Novanta Inc. Announces $300 Million Private Placement
BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares (“Com...